Katy Milne

List of Publications by Year
in descending order

43 papers	5,118 citations	159585 30 h-index	265206 42 g-index
45 all docs	45 docs citations	45 times ranked	9199 citing authors

#	Article	IF	Citations
1	CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27â`' Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. Clinical Cancer Research, 2012, 18, 3281-3292.	7.0	447
2	Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nature Medicine, 2019, 25, 89-94.	30.7	413
3	Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. Clinical Cancer Research, 2016, 22, 3005-3015.	7.0	402
4	Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. PLoS ONE, 2009, 4, e6412.	2.5	354
5	Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2014, 20, 434-444.	7.0	340
6	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Research, 2011, 13, R126.	5.0	315
7	PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecologic Oncology, 2016, 141, 293-302.	1.4	261
8	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 2018, 173, 1755-1769.e22.	28.9	261
9	Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer, 2013, 108, 155-162.	6.4	218
10	PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. Cancer Immunology Research, 2015, 3, 926-935.	3.4	169
11	Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Cancer Discovery, 2020, 10, 406-421.	9.4	155
12	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Modern Pathology, 2012, 25, 740-750.	5.5	151
13	Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer. Clinical Cancer Research, 2014, 20, 1125-1134.	7.0	144
14	CD103 and Intratumoral Immune Response in Breast Cancer. Clinical Cancer Research, 2016, 22, 6290-6297.	7.0	125
15	Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. Clinical Cancer Research, 2017, 23, 925-934.	7.0	125
16	CD74 and intratumoral immune response in breast cancer. Oncotarget, 2017, 8, 12664-12674.	1.8	115
17	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 2537-2548.	7.0	101
18	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. Journal of Translational Medicine, 2012, 10, 33.	4.4	93

#	Article	IF	Citations
19	Clonal evolution of highâ€grade serous ovarian carcinoma from primary to recurrent disease. Journal of Pathology, 2013, 229, 515-524.	4.5	88
20	The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nature Communications, 2018, 9, 3049.	12.8	82
21	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. OncoImmunology, 2018, 7, e1502905.	4.6	80
22	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 569-580.	7.0	79
23	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget, 2020, 11, 2092-2105.	1.8	64
24	Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (Î±E/Î²7) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	59
25	Location, location, location. OncoImmunology, 2014, 3, e27668.	4.6	53
26	Recurrent genomic rearrangements in primary testicular lymphoma. Journal of Pathology, 2015, 236, 136-141.	4.5	47
27	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer, 2017, 17, 618.	2.6	42
28	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. PLoS ONE, 2008, 3, e3409.	2.5	37
29	PD-L1 and intratumoral immune response in breast cancer. Oncotarget, 2017, 8, 51641-51651.	1.8	37
30	Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. , 2019, 7, 13.		37
31	Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells. Cancer Research, 2007, 67, 6442-6450.	0.9	30
32	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Nonâ€"small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600.	2.5	30
33	Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	26
34	Loss of Parkinsonâ€™s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis. Scientific Reports, 2021, 11, 2097.	3.3	22
35	The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. Gynecologic Oncology, 2020, 158, 167-177.	1.4	20
36	CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15â€"Dependent Mechanism. Clinical Cancer Research, 2007, 13, 7172-7180.	7.0	19

#	Article	IF	Citations
37	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers, 2020, 12, 3828.	3.7	19
38	Somatic mutation-associated T follicular helper cell elevation in lung adenocarcinoma. OncoImmunology, 2018, 7, e1504728.	4.6	14
39	Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR). Breast Cancer: Basic and Clinical Research, 2011, 5, BCBCR.S7344.	1.1	11
40	Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. Gynecologic Oncology, 2021, 160, 520-529.	1.4	10
41	Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. Cancer Immunology, Immunotherapy, 2009, 58, 1865-1875.	4.2	9
42	Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model. Breast Cancer Research and Treatment, 2010, 121, 753-763.	2.5	9
43	P2.01-065 Quantification of Tumor-Immune Cell Spatial Relationships in the Lung Tumor Microenvironment Using Single Cell Profiling. Journal of Thoracic Oncology, 2017, 12, S826-S827.	1.1	2